Literature DB >> 35657579

The role of surgery in small differentiated thyroid cancer.

Firas Baidoun1, Omar Abdel-Rahman2.   

Abstract

INTRODUCTION: The incidence of small, differentiated thyroid cancer (DTC) cases has been increasing in the United States and the world mainly due to incidental detection because of widespread use of diagnostic modalities. While the option of active surveillance instead of surgical resection is getting more popular, there is still an open discussion about the best approach in these cases.
MATERIALS AND METHODS: The National Cancer Database was queried for patients diagnosed with non-metastatic small T1/N0 DTC between 2004 and 2016, who have known surgical status and Charlson comorbidity index of two or less. We evaluated the overall survival (OS) based on the surgery status using Kaplan-Meier estimates and multivariable cox regression analyses.
RESULTS: A total of 98,501 patients with non-metastatic small DTC were included, within which 96,612 (98.1%) were treated with surgery, and 1889 (1.9%) were not treated with surgery or other ablative modalities. We found that patients who were treated with surgery had better OS compared to patients who were not treated with surgery (mean OS 171 months vs 134.1 months, P < 0.001, median OS was not reached). This difference was still statistically significant even after we used propensity score matching for age, gender, race, Charlson-Deyo score, tumor size, and histology. On multivariate analysis, surgery was associated with better OS (HR 0.218; 95% CI: 0.196-0.244; P < 0.001). Same trend was found in subgroup analysis when we split the cohort according to tumor size (<1 and ≥1 cm), histology (follicular, papillary and Hurthle cell carcinoma), and age (<55 years vs ≥55 years).
CONCLUSION: Patients with non-metastatic small DTC who were treated with surgery had significant improvement in OS compared to patients who were not treated with surgery. Notwithstanding the limitations of the current analysis, these results call for caution prior to recommending routine surveillance for all patients with small DTC.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Active surveillance; Overall survival; Surgical resection; Thyroid cancer

Mesh:

Year:  2022        PMID: 35657579     DOI: 10.1007/s12020-022-03097-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  8 in total

1.  Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons.

Authors:  Hiroshi Takami; Yasuhiro Ito; Takahiro Okamoto; Akira Yoshida
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

Review 2.  Conservative Surveillance Management of Low-Risk Papillary Thyroid Microcarcinoma.

Authors:  Akira Miyauchi; Yasuhiro Ito
Journal:  Endocrinol Metab Clin North Am       Date:  2018-12-23       Impact factor: 4.741

3.  Papillary thyroid microcarcinoma: an over-treated malignancy?

Authors:  Tracy S Wang; Paolo Goffredo; Julie Ann Sosa; Sanziana A Roman
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

4.  A birth cohort analysis of the incidence of papillary thyroid cancer in the United States, 1973-2004.

Authors:  Cairong Zhu; Tongzhang Zheng; Briseis A Kilfoy; Xuesong Han; Shuangge Ma; Yue Ba; Yana Bai; Rong Wang; Yong Zhu; Yawei Zhang
Journal:  Thyroid       Date:  2009-10       Impact factor: 6.568

Review 5.  Extent of Surgery for Low-Risk Differentiated Thyroid Cancer.

Authors:  Alexandria D McDow; Susan C Pitt
Journal:  Surg Clin North Am       Date:  2019-05-13       Impact factor: 2.741

Review 6.  Systematic Review of Trends in the Incidence Rates of Thyroid Cancer.

Authors:  Joseph J Wiltshire; Thomas M Drake; Lesley Uttley; Sabapathy P Balasubramanian
Journal:  Thyroid       Date:  2016-11       Impact factor: 6.568

Review 7.  New paradigms in the treatment of low-risk thyroid cancer.

Authors:  Firas Baidoun; Anas M Saad; Omar Abdel-Rahman
Journal:  Expert Rev Endocrinol Metab       Date:  2020-06-08

Review 8.  Active surveillance for patients with very low-risk thyroid cancer.

Authors:  Shivangi Lohia; Martin Hanson; R Michael Tuttle; Luc G T Morris
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-02-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.